ModernMedicine Resource Center More Topics

Hepatology Resource Center

DAAs improve patient and graft survival after liver transplantLiver transplant outcomes have improved following the introduction of new hepatitis C virus drugs, according to a new study.
Primary care can manage hep C infections with DAAsPrimary care professionals can “substantially expand” HCV treatment in the community, according to new research.
Report highlights critical actions needed to monitor HCV epidemicA new report highlights key missing elements needed to achieve complete elimination of hepatitis C virus.
Direct-acting antivirals reduce liver cancer riskA sustained response to direct-acting antivirals lowers the risk of hepatocellular carcinoma, a new study finds.
Direct-acting antivirals prevent liver cancer recurrenceNew research finds direct-acting antivirals can be given safely to those on liver transplant waitlist.
Sofosbuvir reduces transplant rate in HCV patientsSofosbuvir-based therapy successfully treats HCV patients with decompensated liver disease, according to a new study.
Triple directing-acting combination treats decompensated liver diseaseA combination of three drugs successfully treats HCV-infected patients with advanced liver disease.
Liver transplant recipients with HCV fare well under drug comboHepatitis C virus infection in liver transplant recipients can be treated with ledipasvir and sofosbuvir without ribavirin.
HBV reactivation with direct acting antivirals for HCV is highly manageableNew study indicates early recognition of HBV-HCV co-infection can lead to prompt treatment of HBV reactivation.
Study: 12 weeks therapy combination cures virtually all HCV patientsA shorter, triple DAA therapy combination is not superior to 12 weeks of sofosbuvir plus velpatasvir in chronic HCV patients, according to researchers.